TOKYO, Mar 13 (Pulse News Wire) – BrightPath Biotherapeutics Co.,Ltd. (4594) has revised its FY2026/3 Full-Year earnings forecast. FORECAST REVISION SUMMARY: (Unit: ) Revenue Op Profit Ord Profit Net Profit Previous Forecast (A) 0 -1,182 -1,164 -1,166 Revised Forecast (B) 0 -1,315 -1,308 -1,311 Change (B-A) - 0 -133 -144 Prior Year Actual 1 -1,160 -1,147 -1,151 KEY CHANGES: - Net profit forecast lowered to -1,311 - Operating profit forecast lowered to -1,315 REASON FOR REVISION: BP2202 BP2202 (41)
Forecast revision — FY2026/3Downward revision
| Metric | Prior | Revised | Change |
|---|---|---|---|
| Revenue | ¥0M | ¥0M | |
| Op. profit | ¥-1,182M | ¥-1,315M | |
| Net profit | ¥-1,166M | ¥-1,311M |
Source: TDNet filing · Figures in millions of yen
🟢 Confidence: High AI-translated content.